GRAd-COV2
AXP000177.1 · Vaccine
- Platform
- gorilla adenovirus (GRAd, non-replicating)
- Targets
- SARS-CoV-2 S
- Originator
- ReiThera
- Sponsor
- ReiThera
Names
| Name | Type | Source |
|---|---|---|
| GRAd-COV2 | preferred name, code | curator, ctgov |
| ReiThera COVID-19 vaccine ambiguous | synonym | ctgov |
Virus
- Role
- Vaccine vector
- Family
- Adenoviridae
- Virus
- gorilla adenovirus
- Replication
- non replicating
- Modifications
- non-replicating great ape (gorilla) adenovirus vector encoding the SARS-CoV-2 spike
- Transgenes
- SARS-CoV-2 spike
- Route
- intramuscular
- Source
- evidence
Approvals
No regulatory approval recorded.
Clinical trials (2)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT04791423 | Study of GRAd-COV2 for the Prevention of COVID-19 in Adults | Completed | Phase 2/3 | 2021-03-15 | 2021-06-04 | 10300 | Covid19 |
| NCT04528641 | Phase I Study to Assess the Safety and Immunology of a COVID-19 Vaccine With GRAd-COV2 Vaccine | Completed | Phase 1 | 2020-08-10 | 2021-05-19 | 98 | COVID-19 |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 37315558 | GRAd-COV2 vaccine provides potent and durable humoral and cellular immunity to SARS-CoV-2 in randomized placebo-controlled phase 2 trial. | Cell reports. Medicine | 2023 | cited by trial NCT04791423 |
| PMID 33895322 | Immunogenicity of a new gorilla adenovirus vaccine candidate for COVID-19. | Molecular therapy : the journal of the American Society of Gene Therapy | 2021 | cited by trial NCT04528641 |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 41746078 | Non-Clinical Safety of GRAd Vector-Based COVID-19 and HIV Vaccines Supports a Platform Regulatory Approach. | Vaccines | 2026 | name in abstract: GRAd-COV2 |
| PMID 34698501 | GRAd-COV2, a gorilla adenovirus-based candidate vaccine against COVID-19, is safe and immunogenic in younger and older adults. | Science translational medicine | 2022 | name in title: GRAd-COV2 |
| PMID 36153335 | Safety and immune response kinetics of GRAd-COV2 vaccine: phase 1 clinical trial results. | NPJ vaccines | 2022 | name in title: GRAd-COV2 |
| PMID 34737309 | Strong immunogenicity of heterologous prime-boost immunizations with the experimental vaccine GRAd-COV2 and BNT162b2 or ChAdOx1-nCOV19. | NPJ vaccines | 2021 | name in title: GRAd-COV2 |
Notes
Single-dose non-replicating gorilla (great ape) adenovirus vector encoding the SARS-CoV-2 spike. The COVITAR trial (NCT04791423) was a completed phase 2/3 study of 10,300 participants, so the program meets the phase 3 bar; never authorised. The vector is usually reported as GRAd32, which the source read does not confirm, so the strain cell is left empty.
How to cite
GRAd-COV2 (AXP000177.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000177.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.